Microengineered Liver Tissues for Drug Testing
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a leading cause of drug attrition. Significant and well-documented differences between animals and humans in liver pathways now necessitate the use of human-relevant in vitro liver models for testing new chemical entities during preclinical drug development. Consequently, several human liver models with various levels of in vivo-like complexity have been developed for assessment of drug metabolism, toxicity, and efficacy on liver diseases. Recent trends leverage engineering tools, such as those adapted from the semiconductor industry, to enable precise control over the microenvironment of liver cells and to allow for miniaturization into formats amenable for higher throughput drug screening. Integration of liver models into organs-on-a-chip devices, permitting crosstalk between tissue types, is actively being pursued to obtain a systems-level understanding of drug effects. Here, we review the major trends, challenges, and opportunities associated with development and implementation of engineered liver models created from primary cells, cell lines, and stem cell-derived hepatocyte-like cells. We also present key applications where such models are currently making an impact and highlight areas for improvement. In the future, engineered liver models will prove useful for selecting drugs that are efficacious, safer, and, in some cases, personalized for specific patient populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in vitro liver systems typically use supraphysiologic concentrations of insulin/glucose and drug concentrations, and lack key elements of the liver microenvironment, including hemodynamics, transport, and multicellularity (5).”
From Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis (2016) · cites this paper as [5]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Geometric Control of Cell Life and Death
Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., & Ingber, D. E. (1997) · Science · doi:10.1126/science.276.5317.1425 · Cited by 4,657 · cited 1×
“In contrast, through the use of selective surface modification, microfabrication tools allow generation of heterogeneous surfaces that offer control over cell-ECM and cell-cell interactions with micrometer precision.(96,97) A variety of such micropatterning techniques are reviewed in other articles.”
BackgroundLutolf, M. P., & Hubbell, J. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1055 · Cited by 4,551 · cited 2×
“Here, we focus on polyethylene-glycol (PEG)–based hydrogels, pioneered by Lutolf and Hubbell.(131) PEG hydrogels are of great interest for cell culture due to their biocompatibility, hydrophilicity, and ability to be customized by varying chain length (to control microporosity and thus mechanical properties) or by che…”
BackgroundRheinwatd, J. G., & Green, H. (1975) · Cell · doi:10.1016/s0092-8674(75)80001-8 · Cited by 4,537
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“However, almost 90% of compounds that pass through preclinical drug screening end up failing during clinical trials, and one-third of these failures have been attributed to toxicity.(3) Furthermore, ~90% of withdrawals of drugs from the marketplace are due to toxicity issues.”
BackgroundMembrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340 · cited 1×
“Both uptake and efflux transporters, distributed over many organs, are now recognized as major contributors to overall drug disposition in the body.(163,164) Thus, a variety of in vitro models have been developed to assess transporter contributions.”
BackgroundHuman induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 1×
“More recently, a handful of groups have tested this so-called coculture effect on iHeps using non–liver NPCs such as murine embryonic Swiss-3T3 fibroblasts as well as a combination of MSCs (mesenchymal stem cells) and HUVECs (human umbilical vein endothelial cells).(89,90) Liver-inspired complex ECM mixtures and ECM d…”
Background
Research works printed but not linked: 2
- Guguen-Guillouzo, 2010, General Review on In Vitro Hepatocyte Models and Their Applications, Methods Mol. Biol., 640, 1, 10.1007/978-1-60761-688-7_1 · DOI · Paper page
- Berger, D. R., Ware, B. R., Davidson, M. D., et al. Enhancing the Functional Maturity of iPSC-Derived Human Hepatocytes via Controlled Presentation of Cell-Cell Interactions In Vitro. Hepatology, in press.
Cited by
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Recent Advances in Body-on-a-Chip Systems
Sung, J. H., Wang, Y. I., Narasimhan Sriram, N., Jackson, M., Long, C., Hickman, J. J., & Shuler, M. L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05293 · Cited by 268
Narayanamurthy, V., Jeroish, Z. E., Bhuvaneshwari, K. S., Bayat, P., Premkumar, R., Samsuri, F., & Yusoff, M. M. (2020) · RSC Advances · doi:10.1039/d0ra00263a · Cited by 233
Beckwitt, C. H., Clark, A. M., Wheeler, S., Taylor, D. L., Stolz, D. B., Griffith, L., & Wells, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.023 · Cited by 208
Microfluidic organ-on-a-chip models of human liver tissue
Moradi, E., Jalili-Firoozinezhad, S., & Solati-Hashjin, M. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.08.041 · Cited by 204
Microfluidic Gut-liver chip for reproducing the first pass metabolism
Choe, A., Ha, S. K., Choi, I., Choi, N., & Sung, J. H. (2017) · Biomedical Microdevices · doi:10.1007/s10544-016-0143-2 · Cited by 189
Engineering 3D Hydrogels for Personalized In Vitro Human Tissue Models
Liaw, C., Ji, S., & Guvendiren, M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701165 · Cited by 170
Liver-Kidney-on-Chip To Study Toxicity of Drug Metabolites
Theobald, J., Ghanem, A., Wallisch, P., Banaeiyan, A. A., Andrade-Navarro, M. A., Taškova, K., Haltmeier, M., Kurtz, A., Becker, H., Reuter, S., et al. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00417 · Cited by 157
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153
“Fourth, in this system, the liver microenvironment is recapitulated by applying physiologically relevant hemodynamics and biological transport, which is absent in traditional static cultures (including many multicellular systems) (5, 7, 8).”
BackgroundMarch, S., Ramanan, V., Trehan, K., Ng, S., Galstian, A., Gural, N., Scull, M. A., Shlomai, A., Mota, M. M., Fleming, H. E., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.128 · Cited by 149
Self-citationReactive Metabolites: Current and Emerging Risk and Hazard Assessments
Thompson, R. A., Isin, E. M., Ogese, M. O., Mettetal, J. T., & Williams, D. P. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00410 · Cited by 140
Characterization of a functional C3A liver spheroid model
Gaskell, H., Sharma, P., Colley, H. E., Murdoch, C., Williams, D. P., & Webb, S. D. (2016) · Toxicology Research · doi:10.1039/c6tx00101g · Cited by 128
A pumpless multi‐organ‐on‐a‐chip (MOC) combined with a pharmacokinetic–pharmacodynamic (PK–PD) model
Lee, H., Kim, D. S., Ha, S. K., Choi, I., Lee, J. M., & Sung, J. H. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26087 · Cited by 124
“Based on recent advances, various organ-on-a-chip microsystems have been developed, including the liver (Khetani et al., 2015), heart (Lee et al., 2015), gastrointestinal tract (Sant et al., 2012), the brain (Pamies et al., 2014), and the kidney (Kim and Roy, 2013).”
BackgroundFernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., Garcia-Ruiz, C., Konu, O., Miranda, J., Lunov, O., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.021 · Cited by 126
“171 This has also been demonstrated using hepatocytes co-cultured with stromal cells present in vivo ( e.g. 174 Whilst an organotypic human liver C3A cell line/HUVEC co-culture system demonstrated profound susceptibility to APAP-induced toxicity in endothelial cells (re fl ecting the situation found…”
MethodHuman-Derived Organ-on-a-Chip for Personalized Drug Development
Jodat, Y. A., Kang, M., Kiaee, K., Kim, G. J., Martinez, A. F. H., Rosenkranz, A., Bae, H., & Shin, S. R. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190308150055 · Cited by 136
Tissue Engineering in Liver Regenerative Medicine: Insights into Novel Translational Technologies
Heydari, Z., Najimi, M., Mirzaei, H., Shpichka, A. I., Ruoß, M., Farzaneh, Z., Montazeri, L., Piryaei, A., Timashev, P. S., Gramignoli, R., et al. (2020) · Cells · doi:10.3390/cells9020304 · Cited by 117
“Liver-on-a-chip systems have been shown to be able to predict possible toxicity and improve the sensitivity of certain drugs which are comparable with in vivo data [89].”
BackgroundFowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 109
Liver organoid as a 3D in vitro model for drug validation and toxicity assessment
Brooks, A., Liang, X., Zhang, Y., Zhao, C.-X., Roberts, M. S., Wang, H., Zhang, L., & Crawford, D. H. G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105608 · Cited by 108
Liver organ-on-chip models for toxicity studies and risk assessment
Messelmani, T., Morisseau, L., Sakai, Y., Legallais, C., Goff, A. L., Leclerc, É., & Jellali, R. (2022) · Lab on a Chip · doi:10.1039/d2lc00307d · Cited by 120
Davidson, M. D., Ballinger, K. R., & Khetani, S. R. (2016) · Scientific Reports · doi:10.1038/srep28178 · Cited by 107
“In this model, PHHs are first organized onto collagen-coated circular domains of empirically optimized dimensions in 24-or 96-well plates using semiconductor-driven soft-lithographic tools and then surrounded by 3T3-J2 fibroblasts.”
InfluentialSelf-citationWare, B. R., Durham, M. J., Monckton, C. P., & Khetani, S. R. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.007 · Cited by 103
“which have been implicated in the ability of these fibroblasts to induce functions in hepatocytes from multiple species.(40) Furthermore, 3T3-J2 fibroblasts have a lack of detectable liver functions, display contact inhibition that avoids overgrowth, and are propagated easily before inclusion in coculture.”
BackgroundSelf-citationEngineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“In particular, static disorganized spheroids and micropatterned co-cultures with murine embryonic fibroblasts have been shown to stabilize PHH functions for at least 4 weeks [6].”
BackgroundInfluentialSelf-citationPrediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes
Lin, C., Shi, J., Moore, A., & Khetani, S. R. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066027 · Cited by 84
“Additionally, the ability to interrogate effects of drug incubations on PHH enzyme levels and subsequently victim drug disposition is important for modeling clinical DDIs (Khetani et al., 2015).”
BackgroundInfluentialSelf-citationPettinato, G., Ramanathan, R., Fisher, R. A., Mangino, M. J., Zhang, N., & Wen, X. (2016) · Scientific Reports · doi:10.1038/srep32888 · Cited by 90
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Davidson, M. D., Kukla, D. A., & Khetani, S. R. (2017) · Integrative Biology · doi:10.1039/c7ib00027h · Cited by 66
Self-citationOn-Chip Construction of Liver Lobules with Self-Assembled Perfusable Hepatic Sinusoid Networks
Ya, S., Ding, W., Li, S., Du, K., Zhang, Y., Li, C., Liu, J., Li, F., Li, P., Luo, T., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00794 · Cited by 61
Lin, N., Zhou, X., Geng, X., Drewell, C., Hübner, J., Zuo-gang, L., Zhang, Y., Xue, M., Marx, U., & Li, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-65817-0 · Cited by 63
Water-Stable Metal–Organic Framework/Polymer Composites Compatible with Human Hepatocytes
Neufeld, M. J., Ware, B. R., Lutzke, A., Khetani, S. R., & Reynolds, M. M. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b05948 · Cited by 68
Self-citationStem cell-derived liver cells for drug testing and disease modeling.
Davidson, M. D., Ware, B. R., & Khetani, S. R. (2015) · PubMed · Cited by 67
Self-citationLiver-on-a-chip devices: the pros and cons of complexity
Dalsbecker, P., Adiels, C. B., & Goksör, M. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00346.2021 · Cited by 64
Microfluidic-Based Multi-Organ Platforms for Drug Discovery
Rezaei Kolahchi, A., Khadem Mohtaram, N., Pezeshgi Modarres, H., Mohammadi, M., Geraili, A., Jafari, P., Akbari, M., & Sanati-Nezhad, A. (2016) · Micromachines · doi:10.3390/mi7090162 · Cited by 53
“The liver has been extensively considered as the prime organ for drug toxicity analyses as most of the drug metabolisms occur in the liver [71,156,157].”
BackgroundKim, J. Y., Seo, E. S., Kim, H., Park, J. W., Lim, D.-K., & Moon, D. W. (2017) · Nature Communications · doi:10.1038/s41467-017-02216-6 · Cited by 56
Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity
Gonzalez, F. J., Fang, Z., & Ma, X. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1032245 · Cited by 45
“New engineered human hepatocytes from inducible stem cells could be used to standardize experimental human liver and hepatocytes [6,7].”
BackgroundThe application of engineered liver tissues for novel drug discovery
Lin, C., Ballinger, K. R., & Khetani, S. R. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1032241 · Cited by 44
“Thus, several types of human liver models ranging in their level of in vivo-like complexity have been developed for the preclinical assessment of drug effects [13-17].”
BackgroundMethodInfluentialSelf-citationMicrofluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
“Engineers are using engineering tools to control the cellular microenvironment, such as semiconductor industrial tools, miniaturization tools, and integration with organs on chips, to improve the stability of PHHs’ functions [14].”
BackgroundKukla, D. A., Crampton, A. L., Wood, D. K., & Khetani, S. R. (2020) · Gene Expression · doi:10.3727/105221620x15868728381608 · Cited by 38
Self-citationDa-silva, F., Boulenc, X., Vermet, H., Compigne, P., Gerbal‐Chaloin, S., Daujat‐Chavanieu, M., Klieber, S., & Poulin, P. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.03.001 · Cited by 40
Fraser, K., Bruckner, D. M., & Dordick, J. S. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00054 · Cited by 50
Peptide-based scaffolds for the culture and maintenance of primary human hepatocytes
MacPherson, D., Bram, Y., Park, J., & Schwartz, R. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-86016-5 · Cited by 36
Recent advances in liver‐on‐chips: Design, fabrication, and applications
Qiu, L., Kong, B., Kong, T., & Wang, H. (2023) · Smart Medicine · doi:10.1002/smmd.20220010 · Cited by 44
Liver microsystems in vitro for drug response
Lee, J.-H., Ho, K.-L., & Fan, S.-K. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0575-0 · Cited by 33
Judging the value of ‘liver-on-a-chip’ devices for prediction of toxicity
Starokozhko, V., & Groothuis, G. M. M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1246537 · Cited by 33
Mimicking the Human Physiology with Microphysiological Systems (MPS)
Sung, J. H., Koo, J., & Shuler, M. L. (2019) · BioChip Journal · doi:10.1007/s13206-019-3201-z · Cited by 34
Tissue Chips and Microphysiological Systems for Disease Modeling and Drug Testing
Donoghue, L., Nguyen, K. T. V., Graham, C., & Sethu, P. (2021) · Micromachines · doi:10.3390/mi12020139 · Cited by 34
Ma, C., Tian, C., Zhao, L. Q., & Wang, J. (2016) · Lab on a Chip · doi:10.1039/c6lc00540c · Cited by 31
Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix
Messelmani, T., Goff, A. L., Souguir, Z., Maes, V., Roudaut, M., Vandenhaute, E., Maubon, N., Legallais, C., Leclerc, É., & Jellali, R. (2022) · Bioengineering · doi:10.3390/bioengineering9090443 · Cited by 33
“However, it is estimated that approximately 90% of molecules that successfully pass the preclinical steps fail during clinical trials [2].”
BackgroundEffects of Moringa oleifera Leaves Extract on High Glucose-Induced Metabolic Changes in HepG2 Cells
Gutiérrez, J. A. S., Valdez-Solana, M. A., Forbes-Hernández, T. Y., Avitia-Domínguez, C. I., García-Vargas, G. G., Salas-Pacheco, J. M., Flores-Herrera, Ó., Téllez‐Valencia, A., Battino, M. A., & Sierra‐Campos, E. (2018) · Biology · doi:10.3390/biology7030037 · Cited by 32
A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes
Ölander, M., Wiśniewski, J. R., Flörkemeier, I., Handin, N., Urdzik, J., & Artursson, P. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2375-9 · Cited by 33
Wei, J., Lu, J., Liu, Y., Yan, S., & Li, X. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb02014c · Cited by 27
Liver Acinus Dynamic Chip for Assessment of Drug-Induced Zonal Hepatotoxicity
Kwon, D., Choi, G., Park, S.-A., Cho, S., Cho, S., & Ko, S. (2022) · Biosensors · doi:10.3390/bios12070445 · Cited by 30
“Therefore, the importance of accurate prediction of drug-induced liver injury in preclinical stages has been emphasized, which increases the need for human liver physiology-relevant in vitro models as alternatives to the conventional models such as animal testing and in vitro culture [11,12].”
BackgroundDanoy, M., Poulain, S., Lereau, M., Kato, S., Scheidecker, B., Kido, T., Miyajima, A., Sakai, Y., Plessy, C., & Leclerc, É. (2020) · Biotechnology Progress · doi:10.1002/btpr.3013 · Cited by 23
A microfluidic thyroid-liver platform to assess chemical safety in humans
Kuehnlenz, J., Karwelat, D., Steger‐Hartmann, T., Raschke, M., Bauer, S., Vural, Ö., Marx, U., Tinwell, H., & Bars, R. (2022) · ALTEX · doi:10.14573/altex.2108261 · Cited by 29
Modulation of human iPSC-derived hepatocyte phenotype via extracellular matrix microarrays
Monckton, C. P., Brougham‐Cook, A., Underhill, G. H., & Khetani, S. R. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.09.013 · Cited by 21
Self-citationOrganoid-driven nanomedicine platform development
Wang, J., Wang, F., Jiang, Y., Bai, L., Chen, X. S., & Su, J. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123611 · Cited by 28
Valdiviezo, A., Brown, G. E., Michell, A. R., Trinconi, C. M., Bodke, V. V., Khetani, S. R., Luo, Y., Chiu, W. A., & Rusyn, I. (2022) · Environmental Health Perspectives · doi:10.1289/ehp12006 · Cited by 19
“2,17 – 30 Recent advancements in liver-based in vitro models, 31 including engineered human liver models, 32 – 34 have improved the capabilities of in vitro systems to mimic physiologically relevant metabolic function of the liver.”
Self-citationLin, C., Romero, R., Sorokina, L. V., Ballinger, K. R., Place, L. W., Kipper, M. J., & Khetani, S. R. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36293 · Cited by 22
Self-citationMicrofabrication of liver and heart tissues for drug development
Brown, G. E., & Khetani, S. R. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0225 · Cited by 19
Self-citationKhetani, S. R. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.005 · Cited by 17
Self-citationGeneration of Scalable Hepatic Micro-Tissues as a Platform for Toxicological Studies
Darakhshan, S., Pour, A. B., Kowsari‐Esfahan, R., Vosough, M., Montazeri, L., Ghanian, M. H., Baharvand, H., & Piryaei, A. (2020) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-020-00272-6 · Cited by 17
Latest impact of engineered human liver platforms on drug development
Monckton, C. P., Brown, G. E., & Khetani, S. R. (2021) · APL Bioengineering · doi:10.1063/5.0051765 · Cited by 18
Self-citationWeaver, J. R., Odanga, J. J., Wolf, K., Piekos, S. C., Biven, M., Taub, M. E., LaRocca, J. L., Thomas, C. T., Byer-Alcorace, A., Chen, J., et al. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105504 · Cited by 16
Zakhariants, A. A., Burmistrova, O., & Poloznikov, A. A. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3651-z · Cited by 16
“This fact necessitates the development of new methods for toxicity evaluation by highly informative in vitro tests based on the use of modern cell technologies [3,9].”
MethodModels and methods for in vitro testing of hepatic gap junctional communication
Maes, M., Yanguas, S. C., Willebrords, J., & Vinken, M. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.09.024 · Cited by 16
“…decade, the field of in vitro toxicology has witnessed the introduction of sophisticated liver-based systems in which the in vivo functional phenotype can be kept for extended periods of time, such as microfluidic liver bioreactors (Khetani et al., 2015; LeCluyse et al., 2012; Lin et al., 2015).”
BackgroundCanalicular domain structure and function in matrix-free hepatic spheroids
Sharma, V., Shrivastava, A., Gallet, B., Karepina, E., Charbonnier, P., Chevallet, M., Jouneau, P., & Deniaud, A. (2019) · Biomaterials Science · doi:10.1039/c9bm01143a · Cited by 15
A body-on-a-chip (BOC) system for studying gut-liver interaction
Sung, J. H. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2020.01.003 · Cited by 19
Daou, N., Viader, A., Cokol, M., Nitzel, A., Chakravarthy, M. V., Afeyan, R., Tramontin, T., Marukian, S., & Hamill, M. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-88913-1 · Cited by 15
Directing Cholangiocyte Morphogenesis in Natural Biomaterial Scaffolds
Smith, Q., Bays, J., Li, L., Shareef, H., Chen, C. S., & Bhatia, S. N. (2021) · Advanced Science · doi:10.1002/advs.202102698 · Cited by 16
Engineered liver tissue in vitro to mimic liver functions and its biomedical applications
Yang, W., Wang, X., & Wang, Z. (2022) · Materials Advances · doi:10.1039/d2ma00144f · Cited by 17
Evaluation of Metabolism of a Defined Pesticide Mixture through Multiple In Vitro Liver Models
Valdiviezo, A., Kato, Y., Baker, E. S., Chiu, W. A., & Rusyn, I. (2022) · Toxics · doi:10.3390/toxics10100566 · Cited by 15
“Additionally, these devices are designed for co-culture conditions, which allows investigators to add supporting cells that can enhance hepatocyte function [45,59].”
BackgroundTong, Y., Ueyama-Toba, Y., Yokota, J., Matsui, H., Kanai, M., & Mizuguchi, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-61544-y · Cited by 14
“Therefore, the development of various in vitro models that are able to maintain the high hepatic functions over the long term and that could predict chronic drug-induced hepatotoxicity in pre-clinical trials has been rigorously pursued 37–39 .”
BackgroundBioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine
Kukla, D. A., & Khetani, S. R. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731016 · Cited by 12
Self-citationRezania, V., Coombe, D., & Tuszyński, J. A. (2020) · Journal of Functional Biomaterials · doi:10.3390/jfb11010013 · Cited by 11
“[18] have given an extensive review of micro-model constructs used in exploring drug-induced liver injury (DILI).”
BackgroundDalsbecker, P., Suominen, S., Faridi, M. A., Mahdavi, R., Johansson, J., Blomqvist, C. H., Goksör, M., Aalto‐Setälä, K., Viiri, L. E., & Adiels, C. B. (2025) · Lab on a Chip · doi:10.1039/d4lc00509k · Cited by 12
Wu, L., Ferracci, G., Wang, Y., Fan, T. F., Cho, N., & Chow, P. K. H. (2019) · RSC Advances · doi:10.1039/c9ra03225h · Cited by 12
Ferrari, E., Ugolini, G. S., Piutti, C., Marzorati, S., & Rasponi, M. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac0454 · Cited by 9
“Plasma ablation uses a stamp of PDMS as a physical mask to protect regions of a protein-coated surface from oxygen plasma such that once the stamp is removed, only the proteins underneath the masked regions are maintained, obtaining micropatterned protein domains available for cell attachment [12, 14].”
Label-Free Monitoring of 3D Tissue Models via Electrical Impedance Spectroscopy
Alexander, F., Eggert, S., & Price, D. T. (2019) · Bioanalytical reviews · doi:10.1007/11663_2018_5 · Cited by 12
A study of cryogenic tissue-engineered liver slices in calcium alginate gel for drug testing
Chen, R., Wang, B., Liu, Y., Lin, R., He, J., & Li, D. (2018) · Cryobiology · doi:10.1016/j.cryobiol.2018.05.002 · Cited by 9
In vitro liver models for toxicological research
Fukunaga, I., & Takebe, T. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101478 · Cited by 9
Theobald, J., Cheng, X., Ghanem, A., Gaitantzi, H., Song, G., Klipp, E., Wodke, J. A. H., Becker, H., Mrowka, R., Breitkopf‐Heinlein, K., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2128-1 · Cited by 9
“2006) and loose their cytochrome activity (Tong et al. 1990; LeCluyse 2001; Khetani et al. 2015), when placed in culture.”
BackgroundAnand, A., Mallick, S. P., Singh, B. N., Shikha, K., Suman, D. K., Tripathi, S., Singh, D., & Srivastava, P. (2022) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-021-0128-8 · Cited by 7
Aratyn-Schaus, Y., & Ramanathan, R. (2016) · Bioanalysis · doi:10.4155/bio-2016-0094 · Cited by 7
Jeong, C. G., Negro, G. D., Getsios, S., & Ekert, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00005-0 · Cited by 13
An All-Human Hepatic Culture System for Drug Development Applications
Odanga, J. J., Gianulis, E. C., Whaley, L., LeCluyse, E. L., Presnell, S. C., & Weaver, J. R. (2023) · Journal of Visualized Experiments · doi:10.3791/65992 · Cited by 8
Vazirzadeh, M., Azarpira, N., Vosough, M., & Ghaedi, K. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101503 · Cited by 7
“illustrated that, in comparison with two-dimensional culture, the cultivation of HepG2/C3A cells in the form of liver spheroids ameliorates albumin secretion, elevates metabolic activity and increases enzyme expressions of phases one and two of liver metabolism [39].”
BackgroundEngineered Human Liver Cocultures for Investigating Drug-Induced Liver Injury
Monckton, C. P., & Khetani, S. R. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_11 · Cited by 6
Self-citationPanday, R., Rogy, K. M., Han, Y. D., & Khetani, S. R. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.03.020 · Cited by 6
“…to 60K HSCs/well) or co-encapsulated alongside iHeps in the microtissues at a ratio of 1 HSC to 8 iHeps (close to the physiologic ratio of 1:12 [33]), which was the lowest possible ratio that could be used in the droplet microfluidic platform while ensuring that the microtissues would contain…”
Self-citationLiver-on-a-Chip (LoC) Models: Case Studies of Academic Platforms and Commercial Products
Benzait, Z., Tomsuk, Ö., Ebrahimi, A., Ghorbanpoor, H., Özel, C., Didarian, R., Cevizlidere, B. D., Kaya, M., Gür, T., Gasimzade, N., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01122 · Cited by 7
Next-generation experimental and computational strategies for drug-drug interaction prophecy
Kanukolanu, A., Nalla, L. V., & Gajula, S. N. R. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100150 · Cited by 4
Huh, D., & Kim, D. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215574458 · Cited by 5
Preparation and Utilization of a 3D Human Liver Microtissue Model for Nanotoxicological Assessment
Kermanizadeh, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8916-4_3 · Cited by 4
A microphysiological model of human MASLD reveals paradoxical response to resmetirom
Hellen, D. J., Ungerleider, J. L., Tevonian, E. N., Sphabmixay, P., Roy, P., Meimetis, N., Presutti, F., Williams, A. M., Ogi, R., Lewis, C. A., et al. (2026) · Communications Biology · doi:10.1038/s42003-025-09484-9 · Cited by 4
“Elevation of ALT, AST, and LDH is observed at day 3, likely due to post-thaw stress 38,39 , but tapers signi fi cantly by day 7 onwards.”
Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy
Beckwitt, C. H. (2018) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 5
Chen, A. X., Chhabra, A., Fleming, H. E., & Bhatia, S. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00041-1 · Cited by 7
George, E., Velayudhan, S., & Kumar, P. R. A. (2022) · Springer eBooks · doi:10.1007/978-981-19-1379-2_15 · Cited by 3
Evaluating the potential hepatotoxicity from hip implant wear products—An in-vitro and in-vivo study
Thakur, S., Kanniyappan, H., Gupta, P., Perumal, G., Hillwig, R., Bodke, V. V., Khetani, S. R., & Mathew, M. T. (2025) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2025.100113 · Cited by 2
“Beyond these local physiological effects, our findings also revealed significant disruptions in hepatocyte function, as indicated by alterations in the synthesis of albumin and urea, which are accepted liver functional markers[56].”
Self-citationFunctional Liver Cell–Based Platforms in Biomedical Research
Hashemian, Z., Taleahmad, S., Shokouhian, B., Najimi, M., & Vosough, M. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70128 · Cited by 4
“This approach enabled researchers to have more accurate studies on drug metabolism and safety [32].”
Huang, L., Zou, S.-X., Deng, J., Dai, T., Jiang, J., Jia, Y., Dai, R., & Xie, S. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.12.008 · Cited by 2
Ware, B. R., & Khetani, S. R. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6661-5_16 · Cited by 2
Self-citation
Metadata
- Authors
- Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R.
- Affiliations
- Colorado State University (US)
- Corresponding author
- Khetani, Salman R.
- Venue
- SLAS Technology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 20
- Issue
- 3
- Pages
- 216-250
- ISSN
- 2472-6303 (ISSN-L)
- OpenAlex
- W2114732687
- Cited by
- 116
- References
- 210
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 1 · 2023: 7 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 7 · 2018: 14 · 2017: 11 · 2016: 18 · 2015: 8
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 2497 d)
- Locations
- SLAS TECHNOLOGY (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- drug-induced liver injury, organ-on-a-chip, hepatocyte-like cells, stem cell-derived hepatocytes, primary hepatocytes, cell lines, drug metabolism, drug toxicity, drug screening, microenvironment control, miniaturization, personalized drug testing
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Liver, Miniaturization, Stem Cells, Hepatocytes, Tissue Engineering, Systems Biology, Chemical and Drug Induced Liver Injury, Lab-On-A-Chip Devices, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.